iLIVER最新文献

{"title":"Visual analysis of mesenchymal stem cell research in liver disease based on bibliometrics","authors":"Chengzuo Han ,&nbsp;Rui Wang ,&nbsp;Nan Xu ,&nbsp;Xuyong Wei ,&nbsp;Qiang Wei ,&nbsp;Xiao Xu","doi":"10.1016/j.iliver.2022.11.006","DOIUrl":"10.1016/j.iliver.2022.11.006","url":null,"abstract":"<div><p>The research of mesenchymal stem cells (MSCs) in the field of liver diseases has received more and more attention. This paper introduces the current situation, hot spots, and development trends in this field. Comprehensive searches were conducted using Web of Science Core Collection from January 1, 2000 to December 13, 2021 with the following keywords: TS(topic) = (liver∗OR hepatic∗OR hepatocyte) AND TS(topic) = (Mesenchymal stem cell∗). VOSviewer (version 1.6.16) and CiteSpace V are used as bibliometric tools to analyze and visualize the knowledge graph. A total of 4452 papers were included in this study, and the number of research papers on MSCs in the field of liver diseases increased from January 2000 to December 2020. Eighty-four countries and regions have published articles on research in this field, among which China and the United States are the main two countries of publication. Based on the keyword burst detection, we find that the research in this field has shifted from basic research to clinical application, from medical research to interdisciplinary research. Tissue engineering and regenerative medicine are the frontier fields of MSCs research in liver diseases. Multicountry, multi-author cooperation, and multi-disciplinary intersection are the research trends in this field. Exocrine body, obesity, and tissue engineering are the hotspots in this field.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"1 4","pages":"Pages 283-291"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947822000834/pdfft?md5=fe3832d64c585360344868fcc6254126&pid=1-s2.0-S2772947822000834-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75843089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Raf kinase inhibitor protein on biological characteristics of hepatocellular carcinoma cells and its potential therapeutic effects","authors":"Zhang Lin ,&nbsp;Zhu Jianhua ,&nbsp;Wu Kai ,&nbsp;Hou Yanhong,&nbsp;Liu Haorun","doi":"10.1016/j.iliver.2022.11.005","DOIUrl":"10.1016/j.iliver.2022.11.005","url":null,"abstract":"<div><h3>Background and aims</h3><p>Raf kinase inhibitor protein (RKIP) is an important member of the phosphatidylethanolamine-binding protein family. This study investigated the inhibitory effect of RKIP on the malignant biological behavior of liver cancer cells in vivo and in vitro.</p></div><div><h3>Methods</h3><p>An RKIP gene expression vector was constructed using the pcDNA3.1 vector and transfected into human hepatoma cell line HepG2 to overexpress the RKIP gene. Growth, proliferation, the cell cycle, apoptosis, migration, and invasion of the cell line were analyzed. For in vivo experiments, the vector was transfected into tumor tissue of hepatoma-bearing animals and then tumor growth was analyzed and compared with the control to assess its anti-tumor effect.</p></div><div><h3>Results</h3><p>Compared with the control group, cell growth in the RKIP gene transfection group (HEP-RKIP) was significantly slower. The average colony formation rate of the HEP-RKIP group was significantly lower than that of the other two groups (<em>p</em> &lt; 0.05). The proportion of HEP-RKIP cells in G0/G1 phase was significantly higher than that of the control group (<em>p</em> &lt; 0.05), while the proportion of cells in G2/M phase was significantly lower than that in the control group (<em>p</em> &lt; 0.05). The apoptosis rate of HEP-RKIP cells was approximately 6.4%, which was significantly higher than that of the control group (<em>p</em> &lt; 0.05). Migration of HEP-RKIP cells was significantly slower than that of the other two groups (<em>p</em> &lt; 0.05). In an inhibition experiment of the liver tumor animal model, the tumor inhibition rate of the RKIP in vivo transfection group was significantly higher than that of each control group (<em>p</em> &lt; 0.05).</p></div><div><h3>Conclusion</h3><p>RKIP inhibits malignant biological behavior of liver cancer cells in vitro and has a tumor inhibitory effect in vivo, which may be a potential target for gene therapy of liver cancer.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"1 4","pages":"Pages 275-282"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947822000822/pdfft?md5=e7e713af36364e9fd469f87674bcc6a5&pid=1-s2.0-S2772947822000822-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84853445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anatomical hepatectomy for achieving textbook outcome for perihilar cholangiocarcinoma treated with curative-intent resection: A multicenter study","authors":"Cheng Chen ,&nbsp;Zhi-Peng Liu ,&nbsp;Wei-Yue Chen ,&nbsp;Xiang Wang ,&nbsp;Yun-Hua Liu ,&nbsp;Yue Wang ,&nbsp;Xing-Chao Liu ,&nbsp;Hai-Ning Fan ,&nbsp;Jie Bai ,&nbsp;Yan Jiang ,&nbsp;Yan-Qi Zhang ,&nbsp;Hai-Su Dai ,&nbsp;Zhi-Yu Chen","doi":"10.1016/j.iliver.2022.10.004","DOIUrl":"10.1016/j.iliver.2022.10.004","url":null,"abstract":"<div><h3>Background and aim</h3><p>The textbook outcome (TO) is a comprehensive measure that is superior to individual measures for analysis of surgical quality of care. Anatomical hepatectomy (AH) is beneficial in terms of short-term outcomes in patients undergoing resection. This study was performed to investigate the association between AH and achieving the TO for patients with perihilar cholangiocarcinoma (pCCA) treated with curative-intent resection.</p></div><div><h3>Methods</h3><p>This study involved patients who underwent curative-intent resection for newly diagnosed pCCA from January 2013 to January 2018 at three hospitals in China. All patients were divided into two groups according to the type of hepatectomy: the AH group and non-AH group. The incidence and distribution of achieving the TO were compared between the two groups. Univariable and multivariable logistic regression analyses were used to identify independently predictive factors associated with achieving the TO in patients with pCCA.</p></div><div><h3>Results</h3><p>In total, 333 patients were enrolled [AH group, 225 (67.6%); non-AH group, 108 (32.4%)]. The incidence of achieving the TO in all patients was 24.3%, and the incidence was significantly higher in the AH than non-AH group (30.7% <em>vs.</em> 11.1%, respectively). Multivariable analysis revealed that AH, total bilirubin concentration of &lt;34 μmol/L, maximum tumor size of &lt;3 cm, no macrovascular invasion, and no lymph node metastasis were independently associated with a higher incidence of achieving the TO.</p></div><div><h3>Conclusions</h3><p>The TO was achieved in approximately one-fourth of patients with pCCA who underwent curative-intent resection. The use of AH was more conducive to achieving the TO in patients with pCCA.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"1 4","pages":"Pages 245-251"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947822000779/pdfft?md5=d18743ca122f9b68c8340eefb4976457&pid=1-s2.0-S2772947822000779-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80185738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Viral diseases in Africa: Preventing the outbreak of acute hepatitis of unknown etiology","authors":"Okereke Promise Udohchukwu ,&nbsp;Innocent Kitandu Paul ,&nbsp;Margareth Richard Mallya ,&nbsp;Matilda K. Basinda ,&nbsp;Sospeter Berling Sospeter ,&nbsp;Juvenali Ruaichi","doi":"10.1016/j.iliver.2022.10.002","DOIUrl":"10.1016/j.iliver.2022.10.002","url":null,"abstract":"<div><p>Hepatitis is an inflammation of the liver. There had been an outbreak of hepatitis of unknown origin among children, where nine pediatric patients in Alabama, United States of America, tested negative for hepatitis viruses (A, B, C, D, and E) and autoimmune conditions. So far, no case has been recorded in Africa. This article seeks to give guidelines on how to prevent its occurrence in Africa. Various literatures were reviewed on the background of hepatitis of unknown origin while focusing on World Health Organization publication as regards the outbreaks in other European countries. Therefore, it is worthy to state that Africa needs to keep its healthcare systems ready to take care of the mechanism by which the outbreak may occur and protect the vulnerable pediatric population from such an outbreak.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"1 4","pages":"Pages 235-236"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277294782200069X/pdfft?md5=06d4e7f713c5c5fa9ad51f34891faad0&pid=1-s2.0-S277294782200069X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73826447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishment of a risk assessment system for complications of hepatectomy based on preoperative variables","authors":"Lining Xu ,&nbsp;Guiping Li ,&nbsp;Bo Yang","doi":"10.1016/j.iliver.2022.09.004","DOIUrl":"10.1016/j.iliver.2022.09.004","url":null,"abstract":"<div><h3>Background and aims</h3><p>To reduce the incidence of postoperative complications, it is important to predict them and intervene before surgery if necessary. However, there is no ideal system to evaluate the overall risk of postoperative complications of liver surgery on the basis of preoperative variables. Therefore, this study aimed to design and validate a risk assessment system to predict postoperative complications of hepatectomy on the basis of preoperative variables.</p></div><div><h3>Methods</h3><p>Binomial logistic regression was used to derive the “hepatectomy overall risk formula” (HORF) for predicting postoperative complications on the basis of preoperative variables.</p></div><div><h3>Results</h3><p>Multivariate analysis revealed that Child–Pugh grade B–C (odds ratio [OR] = 1.984, <em>p</em> = 0.002), medical diseases requiring drug treatment (OR = 1.883, <em>p</em> = 0.003), major hepatectomy (OR = 1.947, <em>p</em> &lt; 0.001), adjacent organ invasion (OR = 3.616, <em>p</em> = 0.023), and preoperative hospital stay &gt;7 days (OR = 1.565, <em>p</em> = 0.004) were independent risk factors for postoperative complications of hepatectomy. The area under the curve for the HORF was 0.736. The optimal cut-off value for predicting complications was 0.32 (32%). The area under the curve for the HORF in the validation dataset was 0.727.</p></div><div><h3>Conclusion</h3><p>The HORF can accurately predict postoperative complications of hepatectomy on the basis of preoperative variables, and thus enables the determination of the necessity for intervention before surgery.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"1 4","pages":"Pages 217-224"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947822000676/pdfft?md5=e32c690b5681fc58beb1e4c4f58f7a1b&pid=1-s2.0-S2772947822000676-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87132244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence-based ultrasound imaging technologies for hepatic diseases","authors":"Longfei Ma ,&nbsp;Rui Wang ,&nbsp;Qiong He ,&nbsp;Lijie Huang ,&nbsp;Xingyue Wei ,&nbsp;Xu Lu ,&nbsp;Yanan Du ,&nbsp;Jianwen Luo ,&nbsp;Hongen Liao","doi":"10.1016/j.iliver.2022.11.001","DOIUrl":"10.1016/j.iliver.2022.11.001","url":null,"abstract":"<div><p>Ultrasound (US) imaging is a non-invasive, real-time, economical, and convenient imaging modality that has been widely used in diagnosing and treating hepatic diseases. Artificial intelligence (AI) technology can predict or make decisions based on the experience of clinical experts and knowledge obtained from training data. This technology can help clinicians improve the detection efficiency and evaluate hepatic diseases, promote clinical treatment of the liver, and predict the response of the liver after treatment. This review summarizes the current rapid development of US technology and related AI methods in the diagnosis and treatment of hepatic diseases. Covered topics include steatosis grading, fibrosis staging, detection of focal liver lesions, US image segmentation, multimodal image registration, and other applications. At present, the field of AI in US imaging is still in its early stages. With the future progress of AI technology, AI-based US imaging can further improve diagnosis, reduce medical costs, and optimize US-based clinical workflow. This technology has broad prospects for application to hepatic diseases.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"1 4","pages":"Pages 252-264"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947822000780/pdfft?md5=05a942ad7540dd450cbd63462a141eae&pid=1-s2.0-S2772947822000780-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75392393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precise cell therapy for liver fibrosis: Endothelial cell and macrophage therapy","authors":"Liping Deng ,&nbsp;Bingjie Wu ,&nbsp;Kaini Liang,&nbsp;Hongen Liao,&nbsp;Yanan Du","doi":"10.1016/j.iliver.2022.11.002","DOIUrl":"10.1016/j.iliver.2022.11.002","url":null,"abstract":"<div><p>Liver fibrosis is typically caused by chronic viral hepatitis and, more recently, fatty liver disease associated with obesity. There are currently no approved drugs for liver cirrhosis, and liver transplantation is limited by donor scarcity, thus driving the investigation of novel therapeutic strategies. The development of liver fibrosis presents with stage- and zone-dependent characteristics that manifest as distinct dynamic changes during vascularization and extracellular matrix (ECM) deposition. However, current cellular therapies do not consider the spatiotemporal variations of liver fibrosis without identifying the precise location and stage to administer the intervention to achieve optimal therapeutic effects. Herein, we focus on endothelial cell (EC) and macrophage therapy for liver fibrosis because of their important roles in regulating the spatiotemporal changes of vascularization and ECM deposition during liver fibrosis progression. Overall, this review summarizes the stage-dependent EC and macrophage therapy for liver fibrosis, elucidates their respective mechanisms, and exemplifies potential strategies to realize precise cell therapy by targeting specific liver zones.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"1 4","pages":"Pages 265-274"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947822000792/pdfft?md5=abba7c1fd4c27429dc4e5db717b3cd51&pid=1-s2.0-S2772947822000792-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88165856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review","authors":"Jingxin Yan ,&nbsp;Manjun Deng ,&nbsp;Shunyu Kong ,&nbsp;Ting Li ,&nbsp;Zhenwu Lei ,&nbsp;Lushun Zhang ,&nbsp;Yutong Zhuang ,&nbsp;Xin He ,&nbsp;Huanwei Wang ,&nbsp;Haining Fan ,&nbsp;Yingxing Guo","doi":"10.1016/j.iliver.2022.10.001","DOIUrl":"10.1016/j.iliver.2022.10.001","url":null,"abstract":"<div><p>Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. With the development of systemic therapies, several studies are currently underway, especially those related to the use of programmed death-1/programmed cell death-ligand 1 (PD-1/PD-L1) immunotherapy. Moreover, studies on transarterial chemoembolization (TACE) and PD-1/PD-L1 immunotherapy have demonstrated some interesting outcomes. This article reviewed the current clinical evidence on the combination of TACE and PD-1/PD-L1 immunotherapy. Overall, our review summarized that a favorable survival time could be achieved using this combination in most patients. However, complications such as hyperprogression should be taken seriously, and the underlying mechanisms need to be explored.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"1 4","pages":"Pages 225-234"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947822000688/pdfft?md5=12c39e93d255971c017128516bd0799d&pid=1-s2.0-S2772947822000688-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90971385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Position statement of Hepatology Society, Dhaka, Bangladesh onManagement of acute variceal bleeding in a resource-limited setting","authors":"T. Ahmad, Shahinul Alam, S. Islam, G. Azam, M. Alam, SKMNazmul Hasan, Golam Mustafa, Motahar Hossain, Md. Akmat Ali, Mobin Khan","doi":"10.1016/j.iliver.2022.11.004","DOIUrl":"https://doi.org/10.1016/j.iliver.2022.11.004","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"99 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76665667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced therapies for congenital biliary tract malformation: From bench to bedside","authors":"Yixuan Shao ,&nbsp;Xinyu Yang ,&nbsp;Hao Chen ,&nbsp;Di Lu ,&nbsp;Yonggang Huang ,&nbsp;Xiao Xu","doi":"10.1016/j.iliver.2022.08.003","DOIUrl":"10.1016/j.iliver.2022.08.003","url":null,"abstract":"<div><p>Congenital biliary tract malformations are a series of rare but extremely serious diseases that mainly include biliary atresia and biliary hypoplasia (referred to as Alagille syndrome). The rapid progression of biliary atresia and Alagille syndrome results in jaundice, cholestatic liver disease, cirrhosis, and even liver failure. In most cases, supportive or clinically specific therapies cannot achieve satisfactory outcomes. Therefore, liver transplantation (especially living donor liver transplantation) may be required. As many studies have elucidated the role of genetic factors and the molecular mechanism of congenital biliary tract malformations, experimental therapies such as organoid transplantation, cell therapy, and immunotherapy have been proved to be feasible. These advanced methods have shown outstanding advantages, particularly in patients with end-stage biliary tract malformations, surgery failure, and other problems that cannot be solved by conventional therapies. This review article discusses the potential pathogenesis of and promising therapeutic strategies for biliary tract malformations.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"1 3","pages":"Pages 159-168"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947822000421/pdfft?md5=0f9cea160b439c80620dd8cc6d2c2d35&pid=1-s2.0-S2772947822000421-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76159180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}